Mode
Text Size
Log in / Sign up
Phase 1 N=51 Randomized Quadruple-blind Prevention

Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis and CVD Risk

Postmenopausal Osteoporosis · Gut Microbiota · Cardiovascular Diseases

Enrolled (actual)
51
Serious AEs
0.0%
Results posted
Oct 2024
Primary outcome: Primary: Bone Mineral Density (BMD) — 1.14; 1.15; 1.17; 1.14 g/cm^2

Study Design & Population

Study type
Interventional
Phase
Phase 1
Interventions
blackcurrant (BC) extract (Drug)
Age
Adult · 45+ yrs
Sex
Female
Sponsor
University of Connecticut
Primary completion
Oct 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Bone Mineral Density (BMD)
1.14; 1.15; 1.17; 1.14; 1.17; 1.16
SECONDARY
Serum Marker of Bone Formation
26.55; 21.21; 32.53; 25.99; 41.79; 26.36
SECONDARY
Plasma Regulator of Bone Metabolism
211.12; 133.99; 256.81; 210.15; 102.09; 284.47
SECONDARY
Changes in Plasma Inflammatory Cytokine
16.73; 15.36; 17.95; 16.66; 15.06; 18.34

Summary

Aim to evaluate the effects of blackcurrant supplementation on changes in gut microbiome, bone mass, and CVD risk factors in adult women.

Eligibility Criteria

Inclusion Criteria

  • perimenopausal or early postmenopausal women aged 45-60 years old
  • not on HRT for at least one year before the initiation of the study
  • maintaining normal exercise level ( 20 cigarettes/day)
  • perimenopausal women with any chance or plan of pregnancy
  • taking prescription medications known to alter bone and Ca metabolism such as calcitonin, bisphosphonates, raloxifene within 3 months before the start of the study
  • taking anabolic agents such as parathyroid hormone, growth hormone, or steroids within 3 months before the start of the study
  • planning any procedure that includes iodine, barium or nuclear medicine isotopes in next 7 months
  • alcohol consumption exceeding 2 drinks/day (approximately 14 g ethanol per drink) or a total of 12/week
  • UConn students and/or employees who any key personnel teach or who report to any key personnel
  • study key personnel, spouses of key personnel, or dependents/relatives of any key personnel.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04431960). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search